GMAB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.02B

+13.62%

0.434

-48.04%

921.55M

+29.43%

0.000

-100%

1.05B

+13.48%

0.000

-100%

Estimates Revision

The market is revising Upward the revenue expectations for Genmab A/S (GMAB) for FY2025, with the revenue forecasts being adjusted by 0.12% over the past three months. During the same period, the stock price has changed by 12.79%.

Revenue Estimates for FY2025

Revise Upward

+0.12%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-89.13%

In Past 3 Month

Stock Price

Go Up

+12.79%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is 41.00 USD with a low forecast of 32.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

1 Sell

Moderate Buy

Current: 31.570

Low

32.00

Averages

41.00

High

48.00

Current: 31.570

Low

32.00

Averages

41.00

High

48.00

H.C. Wainwright

Buy

maintain

$40 -> $41

2025-11-10

Reason

H.C. Wainwright

Price Target

$40 -> $41

2025-11-10

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Genmab to $41 from $40 and keeps a Buy rating on the shares following the Q3 report. Darzalex Faspro is now FDA approved in high-risk smoldering multiple myeloma, the analyst tells investors in a research note.

Citi

Buy -> Neutral

downgrade

$101 -> $97

2025-09-29

Reason

Citi

Price Target

$101 -> $97

2025-09-29

downgrade

Buy -> Neutral

Reason

Citi downgraded Merus (MRUS) to Neutral from Buy with a price target of $97, down from $101, after the company entered into an agreement pursuant to which Genmab (GMAB) will acquire all the shares of Merus for $97.00 per share in an all-cash transaction, representing a transaction value of $8.0B. The firm views the possibility of a competing bid as very low.

Guggenheim

Michael Schmidt

Neutral -> Buy

upgrade

$43

2025-09-23

Reason

Guggenheim

Michael Schmidt

Price Target

$43

2025-09-23

upgrade

Neutral -> Buy

Reason

Guggenheim analyst Michael Schmidt upgraded Genmab to Buy from Neutral with a $43 price target.

JPMorgan

Neutral

maintain

2025-09-11

Reason

JPMorgan

Price Target

2025-09-11

maintain

Neutral

Reason

JPMorgan raised the firm's price target on Genmab to DKK 1,650 from DKK 1,500 and keeps a Neutral rating on the shares.

Deutsche Bank

NULL -> Buy

maintain

2025-08-28

Reason

Deutsche Bank

Price Target

2025-08-28

maintain

NULL -> Buy

Reason

Deutsche Bank raised the firm's price target on Genmab to DKK 1,900 from DKK 1,750 and keeps a Buy rating on the shares.

H.C. Wainwright

Buy

maintain

$35 -> $36

2025-08-15

Reason

H.C. Wainwright

Price Target

$35 -> $36

2025-08-15

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Genmab to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The firm sees potential FDA approval by November 30 for the combination of epcoritamab plus rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma.

Valuation Metrics

The current forward P/E ratio for Genmab A/S (GMAB.O) is 17.97, compared to its 5-year average forward P/E of 38.89. For a more detailed relative valuation and DCF analysis to assess Genmab A/S 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

38.89

Current PE

17.97

Overvalued PE

66.19

Undervalued PE

11.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

28.16

Current EV/EBITDA

8.22

Overvalued EV/EBITDA

54.55

Undervalued EV/EBITDA

1.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

10.16

Current PS

4.64

Overvalued PS

15.83

Undervalued PS

4.48

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GMAB News & Events

Events Timeline

No data

News

8.5

12-12Globenewswire

Genmab Acquires Merus, Anticipates $1 Billion EBITDA by 2029

8.5

12-12Newsfilter

Genmab Acquires Merus, Anticipates $1 Billion EBITDA by 2029

8.5

12-12NASDAQ.COM

Genmab Satisfies Requirements for $97 per Share Merus Tender Offer

People Also Watch

Frequently Asked Questions

What is Genmab A/S (GMAB) stock price today?

The current price of GMAB is 31.57 USD — it has increased 0.83 % in the last trading day.

What is Genmab A/S (GMAB)'s business?

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

What is the price predicton of GMAB Stock?

What is Genmab A/S (GMAB)'s revenue for the last quarter?

Genmab A/S revenue for the last quarter amounts to 1.02B USD, increased 25.25 % YoY.

What is Genmab A/S (GMAB)'s earnings per share (EPS) for the last quarter?

Genmab A/S. EPS for the last quarter amounts to 6.46 USD, increased 121.23 % YoY.

What changes have occurred in the market's expectations for Genmab A/S (GMAB)'s fundamentals?

How many employees does Genmab A/S (GMAB). have?

Genmab A/S (GMAB) has 2682 emplpoyees as of December 15 2025.

What is Genmab A/S (GMAB) market cap?

Today GMAB has the market capitalization of 19.45B USD.